Tastylia OD Strip
Tastylia OD Strip Price range: $ 50,00 through $ 140,00
Back to products
Temsujohn
Temsujohn Price range: $ 55,00 through $ 335,00

Temovate

Price range: $ 42,00 through $ 295,00

Temovate is a highly potent topical corticosteroid designed to effectively treat various inflammatory skin conditions. This medication works by reducing redness, swelling, and itching associated with persistent dermatological issues. It is primarily indicated for the relief of severe inflammatory manifestations, including stubborn cases of psoriasis and eczema. The formula provides targeted action directly to the affected areas for a noticeable improvement in skin health. By calming the local immune response, Temovate helps restore a smoother and more comfortable skin texture.

Active substance: Clobetasol
SKU: Temovate Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Temovate belongs to a class of topical medications known as super-high potency corticosteroids. It is indicated for the short-term treatment of inflammatory and pruritic manifestations of moderate-to-severe corticosteroid-responsive dermatoses in adult patients. Dispensed strictly in accordance with federal prescription regulations in the United States, this medication requires clear adherence to medical supervision.

The active substance, clobetasol propionate 0.05%, reduces redness, swelling, and itching associated with recalcitrant skin conditions. Proper application guidelines must be observed to minimize systemic absorption and mitigate the risk of severe adverse reactions.

Temovate: Essential Patient Information

Parameter Specification
Active ingredient Clobetasol propionate (0.05%)
Therapeutic class Super-high potency topical corticosteroid (Class I)
Dosage forms Topical cream, ointment, scalp solution
Route of administration Topical (dermal application)
Prescription status Prescription (Rx) only
Primary indication Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

How the Drug Works

Clobetasol propionate is a synthetic analog of prednisolone displaying high glucocorticoid activity combined with minimal mineralocorticoid effect. The precise therapeutic mechanism involves induction of phospholipase A2 inhibitory proteins, collectively termed lipocortins. These proteins control the biosynthesis of potent inflammatory mediators, including leukotrienes and prostaglandins, by inhibiting the release of their common precursor, arachidonic acid.

Additionally, the drug induces vasoconstriction of local capillary beds in the dermal layer, which mitigates edema and cellular migration. Through binding to intracellular glucocorticoid receptors, Temovate suppresses inflammatory signaling cascades, thereby rapidly attenuating severe itching, skin thickening, erythema, and localized tissue hyperkeratosis.

Main Uses

Temovate is approved by the US Food and Drug Administration (FDA) for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly plaque psoriasis and severe recalcitrant eczema. It is also indicated for scalp dermatoses when formulated as a topical solution or foam.

Due to its classification as a Class I super-high potency corticosteroid, its administration is reserved for acute, refractory cutaneous conditions that have failed to respond adequately to medium- or high-potency corticosteroids. Off-label application for severe, localized inflammatory lesions such as lichen planus or lichen sclerosus must be directed strictly by a licensed prescriber. It is not indicated for facial lesions, rosacea, acne vulgaris, or perioral dermatitis.

Dosing Schedule

Temovate should be applied sparingly to affected skin areas as a thin film twice daily, gently rubbed in until fully absorbed. Total dosage must not exceed 50 grams (or 50 mL) per week due to the high risk of systemic absorption and hypothalamic-pituitary-adrenal (HPA) axis suppression.

Treatment duration should be limited to two consecutive weeks whenever possible. If full symptom control is achieved prior to 14 days, application should be discontinued or stepped down to a lower-potency agent. Treatment beyond two weeks must be restricted to minimal localized areas and monitored closely by a healthcare provider. Occlusive dressings (such as plastic wrap or tight bandages) must not be utilized unless explicitly instructed by a physician, as occlusion markedly enhances systemic drug absorption.

What Happens in the Body

The extent of percutaneous absorption of clobetasol propionate depends on factors such as formulation integrity, epidermal barrier condition, application site, and the presence of occlusive dressings. Intact skin provides a substantial barrier; however, inflamed, thinned, or broken skin significantly accelerates dermal absorption.

Once absorbed through the skin, clobetasol propionate follows metabolic pathways similar to systemically administered corticosteroids. It is bound to plasma proteins to varying degrees and undergoes hepatic metabolism via hydroxylation and conjugation. Excretion of metabolites occurs primarily through the kidneys, with a smaller proportion eliminated via the biliary system in feces. Systemic bioavailability remains low when applied correctly without occlusion on intact skin surface area.

Practical Tips

Hands must be thoroughly washed with soap and water before and after applying Temovate, unless the hands themselves are the intended treatment area. Patients should apply only enough cream or ointment to cover affected lesions lightly. Care must be taken to avoid accidental contact with eyes, eyelids, mouth, or open wounds; if accidental contact occurs, flush thoroughly with clean water.

Do not apply Temovate to intertriginous areas such as the groin, axillae, or skin folds under breasts due to an increased risk of cutaneous atrophy. Allow the application area to dry fully before wearing tight clothing over treated skin.

Compatibility with Other Medicines

Concomitant use of Temovate with systemic corticosteroids or other topical steroids may increase the risk of systemic corticosteroid toxicity, including corticosteroid-induced side effects and HPA axis suppression. Co-administration with potent CYP3A4 inhibitors (such as ritonavir or itraconazole) can inhibit clobetasol metabolism and elevate systemic steroid exposure.

Mixing Temovate with other topical ointments, creams, or harsh chemical agents on the same lesion site should be avoided, as this may alter drug stability or barrier absorption profiles. Always inform your prescribing provider of all concurrently used topical products, prescription medications, over-the-counter drugs, and dietary supplements.

Adverse Reactions

Local cutaneous adverse reactions are the most common side effects associated with Temovate application. These include localized burning, stinging, itching, dryness, hypertrichosis, acneiform eruptions, hypopigmentation, folliculitis, and skin atrophy (thinning). Prolonged use or excessive application may lead to striae (stretch marks), telangiectasia (visible dilated capillaries), and secondary skin infections.

Systemic adverse events, though less common with short-term proper use, stem from percutaneous absorption and include HPA axis suppression, Cushingoid features, hyperglycemia, glucosuria, and intracranial hypertension. Pediatric patients are at a higher risk of systemic toxicity due to a larger skin surface area-to-body weight ratio.

Red Flags

Immediate medical evaluation is necessary if signs of systemic absorption or localized severe complications develop during therapy.

Clinical Manifestation Recommended Action
Swelling of face, lips, tongue, or throat Seek emergency medical care immediately
Severe cutaneous burning, blistering, or skin peeling Discontinue use and contact your prescriber
Signs of secondary skin infection (pus, severe warmth) Consult your healthcare provider promptly
Extreme fatigue, weight loss, or dizziness (Adrenal crisis) Seek immediate medical evaluation
Vision changes or severe eye irritation Flush with water and seek prompt medical attention

Special Populations

Pediatric Use: Safety and effectiveness of Temovate in pediatric patients under 12 years of age have not been established. Children absorb larger proportional amounts of topical corticosteroids, increasing vulnerability to systemic HPA axis suppression, Cushing’s syndrome, and growth retardation.

Pregnancy & Lactation: Temovate is classified as Pregnancy Category C. It should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. It is unknown whether topical administration leads to detectable levels in human breast milk; cautious administration and avoiding application directly to the breast area prior to nursing are required.

Geriatric Use: Clinical studies have not demonstrated distinct responses between elderly and younger patients, but lower hepatic or renal function in older adults requires prudent clinical monitoring.

If You Skip a Dose

If a dose of Temovate is missed, apply the thin layer as soon as remembered, provided it is not almost time for the next scheduled application. If the next application time is approaching, skip the missed dose and resume the normal daily dosing routine.

Double application or applying excessive quantities of the cream to make up for a missed dose is contraindicated, as this elevated load significantly increases local cutaneous adverse reactions and systemic steroid absorption.

Important Precautions

Temovate is contraindicated in patients with a history of hypersensitivity to clobetasol propionate or any excipient in the formulation. Treatment must not be initiated on areas with active untreated viral, fungal, or tuberculous cutaneous infections, such as herpes simplex or varicella.

Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal. Diagnostic assessment for HPA axis suppression using the cosyntropin stimulation test may be performed if broad application or occlusive dressing is utilized. Discontinue therapy gradually if used over extended skin surfaces to prevent rebound flares of the underlying dermatosis.

Common Questions

Can Temovate be applied directly to the face for a skin rash?

No, Temovate should not be applied to the face unless explicitly directed and monitored by a healthcare provider. The skin on the face is exceptionally thin and sensitive, making it significantly more susceptible to side effects such as skin atrophy, telangiectasia, rosacea-like eruptions, and systemic absorption. Lower-potency topical steroids are generally preferred for facial dermatoses.

How long can Temovate safely be used continuously?

The standard clinical recommendation is to limit continuous use of Temovate to no more than two consecutive weeks. Because it is a Class I super-high potency corticosteroid, extended use dramatically increases the risk of local skin thinning, stretch marks, and suppression of the body’s natural hormone production via the HPA axis.

What happens if Temovate treatment is suddenly stopped?

Abrupt discontinuation of high-potency topical steroids after prolonged or widespread use can lead to a rebound flare, where the underlying skin condition reappears with heightened severity. To prevent this, prescribers often recommend gradually tapering the frequency of application or stepping down to a lower-potency corticosteroid product.

Is it safe to cover the applied skin with a bandage or plastic wrap?

You should never cover the treated area with an occlusive dressing, such as plastic wrap, tight bandages, or waterproof coverings, unless specifically instructed by your physician. Occlusion dramatically increases skin penetration and systemic absorption of clobetasol propionate, significantly raising the risk of severe side effects.

Can Temovate be used to treat fungal skin infections like ringworm?

No, Temovate is not an antimicrobial or antifungal medication. Applying a powerful corticosteroid to a fungal, viral, or bacterial infection can suppress the local immune response, allowing the pathogen to spread and worsening the infection. Proper diagnosis by a healthcare provider is required before treating any unidentified skin eruption.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

15 g

,

30 g

Package

2 tubes

,

4 tubes

,

6 tubes

,

10 tubes

,

12 tubes

Ενεργός Ουσία